Bluebird bio's GAAP loss for 2022 was $266.58 million, a three-fold decrease from $819.38 million in the previous year. Revenues fell 1.8% to $3.597 million from $3.662 million a year earlier.
Bluebird bio's GAAP loss for 2022 was $266.58 million, a three-fold decrease from $819.38 million in the previous year. Revenues fell 1.8% to $3.597 million from $3.662 million a year earlier. 
investor.bluebirdbio.com
English (US) 